leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...113114115116117118119120121122123...235236»
  • ||||||||||  irinotecan / Generic mfg.
    Journal:  Skin Toxicities During Colorectal Cancer Chemotherapy: Incidence and Pearls of Treatment in Our Experience. (Pubmed Central) -  Nov 24, 2021   
    A dermatologic visit is useful, both for the correct diagnosis of and for the adequate therapy of chemotherapy side effects. The prevention and treatment of these toxicities are important, not only to improve quality of life but also to avoid unnecessary dose reduction or interruption, which can have a negative effect on treatment outcome.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD. (Pubmed Central) -  Nov 24, 2021   
    An African-American female underwent 5-fluorouracil-based therapy (400 mg/m bolus, 1200 mg/m/day over 46 h)...After a 1000 mg/m/day dose resulted in myelosuppression, 5-FU was again de-escalated for the remaining cycles (600 mg/m). The observed complications are likely a function of uncommon genetic variants that affect DPYD metabolism.
  • ||||||||||  certepetide (LSTA1) / Lisata Therap, Vectibix (panitumumab) / Amgen
    Enrollment open:  CENDIFOX: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (clinicaltrials.gov) -  Nov 24, 2021   
    P1b/2a,  N=50, Recruiting, 
    Resection of LAPC following FOLFIRINOX was associated with increased OS and 3-year survival, as compared to propensity-score matched patients treated with FOLFIRINOX-only. Not yet recruiting --> Recruiting
  • ||||||||||  oxaliplatin / Generic mfg., capecitabine / Generic mfg.
    Enrollment open:  PECORINO: Perioperative Chemotherapy in Gastric Cancer (clinicaltrials.gov) -  Nov 22, 2021   
    P2,  N=284, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> May 2021 | Trial primary completion date: Jun 2022 --> May 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Review, Journal:  Surgery for locally advanced pancreatic ductal adenocarcinoma-is it only about the vessels? (Pubmed Central) -  Nov 21, 2021   
    Over the last years and decades, paradigms have shifted in PDAC treatment and potent multidrug chemotherapy protocols, including gemcitabine plus nab-paclitaxel and FOLFIRINOX, result in sufficient downstaging of advanced tumors in many patients...An emphasis is put on arterial and venous resections and their outcome. In the end, we discuss current gaps in the literature and propose directions future research endeavors should focus on.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Review, Journal:  Can local ablative techniques replace surgery for locally advanced pancreatic cancer? (Pubmed Central) -  Nov 21, 2021   
    The "inconvertible LAPC" label requires persistent unresectability after staging and induction therapy of LAPC according to current guidelines followed by liberal indication for aggressive surgical exploration at a center equipped for extended pancreatic resections. Ideally, this specification of a new, distinct patient group will also put it in the spotlight more, hopefully prompt more trials designed to generate robust evidence and optimize transferability of study results.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Review, Journal:  Folic Acid and Autism: A Systematic Review of the Current State of Knowledge. (Pubmed Central) -  Nov 21, 2021   
    Folic acid and/or folinic acid supplementation in autism spectrum disorder diagnosed children has led to improvements, both in some neurologic and behavioral symptoms and in the concentration of one-carbon metabolites...Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk. More clinical trials, with a clear study design, with larger sample sizes and longer observation periods are necessary to be carried out to better evaluate the potential protective role of folic acid in autism spectrum disorder risk.
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Journal:  Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening. (Pubmed Central) -  Nov 21, 2021   
    More clinical trials, with a clear study design, with larger sample sizes and longer observation periods are necessary to be carried out to better evaluate the potential protective role of folic acid in autism spectrum disorder risk. Altogether, we provide a short report showing the feasibility of generating and analyzing with single-cell resolution zAvatars from pancreatic and ampullary cancers, with potential use for future preclinical studies and personalized treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Enrollment change, Metastases:  Escalated Dose of Irinotecan in mCRC (clinicaltrials.gov) -  Nov 17, 2021   
    P=N/A,  N=213, Completed, 
    In chemorefractory patients, this protocol shows a high response rate. Recruiting --> Completed | N=320 --> 213
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Clinical, Clinical data, Journal:  The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. (Pubmed Central) -  Nov 17, 2021   
    Combination chemotherapy, either modified FOLFIRINOX (mFFX) or gemcitabine-nabpaclitaxel, are used in the treatment of most patients with advanced pancreatic ductal adenocarcinoma (PDAC), yet robust biomarkers of outcome are currently lacking to guide regimen selection...Our results provide strong evidence that GATA6 IHC can be used as a single biomarker in the clinic to predict clinical outcome in advanced PDAC, warranting further investigation in prospective clinical trials. These results provide the basis for an improved classification of PDAC and future biomarker design using digital pathology workflow.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. (Pubmed Central) -  Nov 17, 2021   
    Among these, 118 (33.2%), 66 (18.6%), and 11 (3.1%) received a maintenance with 5-fluorouracil/leucovorin (5FU/LV)+anti-EGFR, anti-EGFR, and 5FU/LV, respectively, while 160 (45.1%) patients continued induction treatment (non-maintenance) until disease progression, unacceptable toxicity, patient decision, or completion of planned treatment...Any grade non-hematological and hematological events were generally higher in the non-maintenance compared to the maintenance cohorts. Among the treatment strategies following an anti-EGFR-based doublet first-line induction regimen in patients affected by left-sided RAS/BRAF wild-type mCRC treated in a "real-life" setting, 5FU/LV+anti-EGFR resulted the most adopted, effective, and relatively safe regimen.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Preclinical, Journal:  The Effects of 5-Fluorouracil/Leucovorin Chemotherapy on Cognitive Function in Male Mice. (Pubmed Central) -  Nov 17, 2021   
    Tandem mass tag proteomics analysis identified 6,049 proteins, 7 of which were differentially expressed with a p-value of 1.5. The present data demonstrate that 5-Fu/LV increases anxiety and significantly impairs spatial memory retention.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Venous thromboembolism (VTE) in pancreatic cancer patients – single centre experience ([VIRTUAL]) -  Nov 16, 2021 - Abstract #NCRI2021NCRI_291;    
    30% of patients in the audit who developed VTE were on Gemcitabine alone, 28% were on Gemcitabine based combination chemotherapy, and 18% were on the FOLFIRINOX regimen...We now routinely include thromboprophylaxis for all pancreatic cancer patients who are on chemotherapy unless contraindicated. Impact statement Thromboprophylaxis may reduce the risk of life threatening venous thrombo-embolic events and complications in pancreatic cancer patients undergoing chemotherapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
    Clinical, Journal:  A case of pembrolizumab responding to recurrent small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome (Pubmed Central) -  Nov 16, 2021   
    However, local recurrence was noted, and the tumor increased even after CapeOX plus bevacizumab and fluorouracil plus leucovorin plus irinotecan plus panitumumab (FOLFIRI plus panitumumab). Pembrolizumab was administered after confirming high-frequency microsatellite instability, and the tumor shrank markedly and remained shrunk for 20 months.